Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.00, up 4.77% in the last 24 hours. The technical outlook is bullish, supported by moving averages, though the RSI suggests mild overbought conditions. Recent corporate actions include two stock splits effective June 2026. The fund provides leveraged exposure to NVIDIA, which remains a dominant force in AI, but key financial ratios for NVDL itself are not publicly detailed as it is an ETF tracking daily returns.

The outlook for NVDL hinges on NVIDIA's performance, with bullish technicals and media sentiment pointing to potential gains, especially around earnings. However, risks include high volatility from daily leverage reset, which can amplify losses during NVIDIA downturns, as seen in past sharp declines. Investors should weigh the leveraged structure's compounding effects against NVIDIA's strong AI-driven growth trajectory.

Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.

Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.